Register Login

TRAWS PHARMA, INC. (TRAW)

SymbolTRAW
NameTRAWS PHARMA, INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Pharmaceutical Preparations
Address12 PENNS TRAIL, NEWTOWN, Pennsylvania, 18940, United States
Telephone+1 267 759-3680
Fax—
Email—
Websitehttps://www.onconova.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK0001130598
Description

Traws Pharma, Inc., formerly Onconova Therapeutics, Inc., is a virology and oncology company. The Company is engaged in developing antivirals for influenza, COVID and other respiratory infections and narazaciclib. Its proprietary portfolio includes, TRX100 (viroksavir), TRX01 (travaltrevir), and Narazaciclib. Viroksavir is a cap-dependent endonuclease inhibitor for influenza. Travaltrevir is a Mpro protease inhibitor for COVID19. Narazaciclib is a cyclin-dependent kinases (CDK) 4/6 inhibitor for low-grade endometrioid endometrial cancer (LGEEC). Narazaciclibs mechanism of action in LGEEC is validated by phase II studies with other approved CDK4/6 inhibitors: palbociclib, ribociclib, and abemaciclib. Narazaciclib is in phase I/IIa study to define the Phase II dose (RP2D).

Additional info from NASDAQ:
Traws Pharma, Inc., formerly Onconova Therapeutics, Inc., is a virology and oncology company. The Company is engaged in developing antivirals for influenza, COVID and other respiratory infections and narazaciclib. Its proprietary portfolio includes, TRX100 (viroksavir), TRX01 (travaltrevir), and Narazaciclib. Viroksavir is a cap-dependent endonuclease inhibitor for influenza. Travaltrevir is a Mpro protease inhibitor for COVID19. Narazaciclib is a cyclin-dependent kinases (CDK) 4/6 inhibitor for low-grade endometrioid endometrial cancer (LGEEC). Narazaciclibs mechanism of action in LGEEC is validated by phase II studies with other approved CDK4/6 inhibitors: palbociclib, ribociclib, and abemaciclib. Narazaciclib is in phase I/IIa study to define the Phase II dose (RP2D).

2026-08-14 22:17

New Form SCHEDULE 13G/A - Traws Pharma, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001193125-26-352962 <b>Size:</b> 13 KB

Read more
2026-08-14 20:30

(30% Negative) TRAWS PHARMA, INC. (TRAW) Reports Q3 2026 Financial Results

Read more
2026-08-14 20:30

Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights

Read more
2026-08-14 14:26

New Form SCHEDULE 13G/A - Traws Pharma, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0002050709-26-000026 <b>Size:</b> 79 KB

Read more
2026-08-14 09:37

New Form SCHEDULE 13G - Traws Pharma, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0000919574-26-005209 <b>Size:</b> 16 KB

Read more
2026-08-12 13:01

New Form SCHEDULE 13G/A - Traws Pharma, Inc. <b>Filed:</b> 2026-08-12 <b>AccNo:</b> 0000919574-26-004949 <b>Size:</b> 12 KB

Read more
2026-08-06 02:49

NASDAQ symbol attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.

Read more
2026-08-06 01:39

NASDAQ traded attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.

Read more
2026-07-31 20:15

(99% Neutral) TRAWS PHARMA, INC. (TRAW) Files Form 8-K

Read more
2026-07-16 16:39

Pauza Charles David 🟢 acquired 97.0K shares (1 derivative) of Traws Pharma, Inc. (TRAW) at $0.68 Transaction Date: Jul 09, 2026 | Filing ID: 000003

Read more
Trial ID Title Phase Indication Status Start Date Completion Date Source
NCT07503405 Phase 2a Study of the Efficacy and Safety of TRX-100 in a Human Influenza A Cha… Phase2 Influenza Not_Yet_Recruiting 2026-06-01 2027-04-01 ClinicalTrials.gov
NCT07526506 Study of TRX-100 Evaluating the Safety, Pharmacokinetics, and Food Effect in He… Phase1 Healthy Volunteer Recruiting 2026-03-25 2027-02-01 ClinicalTrials.gov
NCT07371650 This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose fo… Phase2 Influenza Active_Not_Recruiting 2025-12-15 2027-01-01 ClinicalTrials.gov
NCT07157007 Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Pat… Phase2 COVID - 19 Recruiting 2025-09-16 2026-03-01 ClinicalTrials.gov
NCT06757738 A Clinical Study Aiming to Assess Pharmacokinetics, Pharmacodynamics and Prelim… Phase1 Healthy Volunteer Study Completed 2024-08-13 2025-01-24 ClinicalTrials.gov
NCT06402136 Evaluation Safety, Tolerability, and Pharmacokinetics of Single and Multiple As… Phase1 Healthy Volunteers Only Completed 2024-04-15 2024-09-30 ClinicalTrials.gov
NCT05705505 Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Othe… Phase1 Endometrioid Endometrial Cancer Unknown 2023-03-29 2026-02-01 ClinicalTrials.gov
NCT04177498 Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associat… Early_Phase1 Recessive Dystrophic Epidermolysis Bullosa Completed 2021-08-24 2025-05-05 ClinicalTrials.gov
NCT04739293 Study of ON 123300 in Patients With Advanced Cancer Phase1 Solid Tumors, Adult Unknown 2021-05-13 2024-10-01 ClinicalTrials.gov
NCT04263090 Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line… Phase1 Non-small Cell Lung Cancer Completed 2020-06-29 2023-12-20 ClinicalTrials.gov
NCT02730884 Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With… Phase2 Leukemia Terminated 2017-08-16 2019-08-22 ClinicalTrials.gov
NCT02562443 Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Pa… Phase3 Myelodysplastic Syndrome Terminated 2015-12-02 2021-07-26 ClinicalTrials.gov
NCT02168725 Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Soli… Phase1 Neoplasms Terminated 2014-06-01 2015-12-01 ClinicalTrials.gov
NCT02075034 Three Dosing Schedules of Oral Rigosertib in MDS Patients Phase1 Myelodysplastic Syndrome Withdrawn 2014-05-01 2019-11-01 ClinicalTrials.gov
NCT02030639 Metabolism and Excretion of [14C]-Rigosertib After Infusion to Volunteers Phase1 Healthy Completed 2014-01-01 2015-08-01 ClinicalTrials.gov
NCT02107235 Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer Phase1 Head and Neck Neoplasms Completed 2014-01-01 2015-01-01 ClinicalTrials.gov
NCT01928537 Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progres… Phase3 Myelodysplastic Syndromes Completed 2013-08-01 2017-06-29 ClinicalTrials.gov
NCT01926587 Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine Phase1 Myelodysplastic Syndrome Completed 2013-08-01 2021-02-16 ClinicalTrials.gov
NCT01904682 Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs Phase2 Myelodysplastic Syndromes Completed 2013-07-01 2021-05-01 ClinicalTrials.gov
NCT01807546 Oral Rigosertib for Squamous Cell Carcinoma Phase2 Head and Neck Squamous Cell Carcinoma Completed 2013-03-01 2016-04-01 ClinicalTrials.gov
NCT01584531 Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 o… Phase2 Myelodysplastic Syndrome Completed 2012-05-01 2015-11-01 ClinicalTrials.gov
NCT01360853 Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer Phase3 Metastatic Pancreatic Adenocarcinoma Completed 2011-05-01 2015-12-01 ClinicalTrials.gov
NCT01241500 Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients… Phase3 Myelodysplastic Syndromes Completed 2010-11-01 2018-10-03 ClinicalTrials.gov
NCT01168011 Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumo… Phase1 Solid Tumor Completed 2010-07-01 2015-12-01 ClinicalTrials.gov
NCT01167166 Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Mye… Phase1 Acute Myelocytic Leukemia Completed 2010-07-01 2014-06-01 ClinicalTrials.gov
NCT01165905 Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Ad… Phase1 Solid Tumor Completed 2010-01-01 2011-07-01 ClinicalTrials.gov
NCT01048619 Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysp… Phase1 Myelodysplastic Syndrome Completed 2009-12-01 2015-12-01 ClinicalTrials.gov
NCT01049113 Safety Study of ON 013105 in Lymphoma and Acute Lymphoid Leukemia Phase1 Lymphoma Terminated 2009-11-01 2015-12-01 ClinicalTrials.gov
NCT00906334 Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients W… Phase2 Myelodysplastic Syndrome Completed 2009-05-01 2013-11-01 ClinicalTrials.gov
NCT00856791 Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients Phase2 Ovarian Cancer Completed 2009-03-01 2011-07-01 ClinicalTrials.gov
NCT00867061 Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or Hig… Phase1 Myelodysplastic Syndrome Withdrawn 2009-03-01 2010-09-01 ClinicalTrials.gov
NCT00854945 Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML Phase1 Myelodysplastic Syndrome Completed 2009-01-01 2014-02-01 ClinicalTrials.gov
NCT01125891 Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors Phase1 Malignant Neoplasmas Completed 2009-01-01 2011-09-01 ClinicalTrials.gov
NCT00854646 Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome… Phase1 Acute Myelocytic Leukemia Completed 2008-10-01 2015-12-01 ClinicalTrials.gov
NCT00861783 Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients… Phase1 Hepatoma Completed 2008-06-01 2011-07-01 ClinicalTrials.gov
NCT00861328 Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin Phase1 Advanced Solid Tumors Completed 2008-02-01 2011-07-01 ClinicalTrials.gov
NCT01538537 Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced Cancer Phase1 Advanced Cancer Completed 2006-08-01 2012-01-01 ClinicalTrials.gov
NCT01538563 Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer Phase1 Solid Tumors Completed 2006-06-01 2011-11-01 ClinicalTrials.gov
Total clinical trials: 38
Product Name Type Development Stage Therapeutic Area Study Status Trial ID
Placebo Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07526506
TRX-100 Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07526506
best supportive care (BSC) Other Phase PHASE3 Myelodysplastic Syndrome TERMINATED NCT02562443
Any approved or standard-of-care therapy Drug Phase PHASE3 Myelodysplastic Syndrome TERMINATED NCT02562443
rigosertib Other Phase PHASE3 Myelodysplastic Syndrome TERMINATED NCT02562443
ON 013105 Other Phase PHASE1 Lymphoma TERMINATED NCT01049113
Gemcitabine Other Phase PHASE3 Metastatic Pancreatic Adenocarcinoma COMPLETED NCT01360853
ON 01910.Na Other Phase PHASE3 Metastatic Pancreatic Adenocarcinoma COMPLETED NCT01360853
Radiotherapy Drug Phase PHASE1 Head and Neck Neoplasms COMPLETED NCT02107235
cisplatin Other Phase PHASE1 Head and Neck Neoplasms COMPLETED NCT02107235
oral rigosertib Other Phase PHASE1 Head and Neck Neoplasms COMPLETED NCT02107235
rigosertib Other Phase PHASE1 Healthy COMPLETED NCT02030639
rigosertib sodium Other Phase PHASE1 Solid Tumors COMPLETED NCT01538563
rigosertib sodium Other Phase PHASE1 Advanced Cancer COMPLETED NCT01538537
rigosertib Other Phase PHASE1 Solid Tumor COMPLETED NCT01168011
Gemcitabine Other Phase PHASE1 Solid Tumor COMPLETED NCT01165905
ON 01910.Na Other Phase PHASE1 Solid Tumor COMPLETED NCT01165905
ON 01910.Na Other Phase PHASE1 Malignant Neoplasmas COMPLETED NCT01125891
gemcitabine Other Phase PHASE1 Malignant Neoplasmas COMPLETED NCT01125891
ON 01910.Na Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT01048619
rigosertib Other Phase PHASE2 Head and Neck Squamous Cell Carcinoma COMPLETED NCT01807546
rigosertib Other Phase PHASE2 Myelodysplastic Syndrome COMPLETED NCT01584531
rigosertib Other Phase PHASE1 Acute Myelocytic Leukemia COMPLETED NCT01167166
rigosertib sodium Other Phase PHASE3 Myelodysplastic Syndromes COMPLETED NCT01928537
ON 01910.Na Other Phase PHASE3 Myelodysplastic Syndromes COMPLETED NCT01241500
rigosertib Other Phase PHASE1 Myelodysplastic Syndrome WITHDRAWN NCT02075034
Questionnaire Other Phase PHASE2 Leukemia TERMINATED NCT02730884
Rigosertib Other Phase PHASE2 Leukemia TERMINATED NCT02730884
Azacitidine Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT01926587
oral rigosertib Other Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT01926587
Oral rigosertib Other Phase PHASE2 Myelodysplastic Syndromes COMPLETED NCT01904682
briciclib Other Phase PHASE1 Neoplasms TERMINATED NCT02168725
ON123300 Other Phase PHASE1 Solid Tumors, Adult UNKNOWN NCT04739293
Letrozole 2.5mg Other Phase PHASE1 Endometrioid Endometrial Cancer UNKNOWN NCT05705505
Narazaciclib Other Phase PHASE1 Endometrioid Endometrial Cancer UNKNOWN NCT05705505
Nivolumab Other Phase PHASE1 Non-small Cell Lung Cancer COMPLETED NCT04263090
Rigosertib Other Phase PHASE1 Non-small Cell Lung Cancer COMPLETED NCT04263090
Quality-of-Life Assessment Other Phase EARLY_PHASE1 Recessive Dystrophic Epidermolysis Bullosa COMPLETED NCT04177498
Rigosertib Sodium Other Phase EARLY_PHASE1 Recessive Dystrophic Epidermolysis Bullosa COMPLETED NCT04177498
Ratutrelvir (83-0060) Other Phase PHASE2 COVID - 19 RECRUITING NCT07157007
Paxlovid Other Phase PHASE2 COVID - 19 RECRUITING NCT07157007
Ratutrelvir (83-0060) non-randomised Other Phase PHASE2 COVID - 19 RECRUITING NCT07157007
Placebo Other Phase PHASE1 Healthy Volunteer Study COMPLETED NCT06757738
TRX-100 Other Phase PHASE1 Healthy Volunteer Study COMPLETED NCT06757738
Placebo Other Phase PHASE1 Healthy Volunteers Only COMPLETED NCT06402136
83-0060 Other Phase PHASE1 Healthy Volunteers Only COMPLETED NCT06402136
Standard of Care (SOC) Other Phase PHASE2 Influenza ACTIVE_NOT_RECRUITING NCT07371650
TRX-100 Other Phase PHASE2 Influenza ACTIVE_NOT_RECRUITING NCT07371650
TRX-100 or placebo Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07526506
Influenza A/France/759/2021 (H1N1) virus BIOLOGICAL Phase PHASE2 Influenza NOT_YET_RECRUITING NCT07503405
Standard of Care (SOC) DRUG Phase PHASE2 Influenza ACTIVE_NOT_RECRUITING NCT07371650
Ratutrelvir (83-0060) DRUG Phase PHASE2 COVID - 19 RECRUITING NCT07157007
Paxlovid DRUG Phase PHASE2 COVID - 19 RECRUITING NCT07157007
Ratutrelvir (83-0060) non-randomised DRUG Phase PHASE2 COVID - 19 RECRUITING NCT07157007
TRX-100 DRUG Phase PHASE2 Influenza NOT_YET_RECRUITING NCT07503405
Placebo DRUG Phase PHASE2 Influenza NOT_YET_RECRUITING NCT07503405
83-0060 DRUG Phase PHASE1 Healthy Volunteers Only COMPLETED NCT06402136
Letrozole 2.5mg DRUG Phase PHASE1 Endometrioid Endometrial Cancer RECRUITING NCT05705505
Narazaciclib DRUG Phase PHASE1 Endometrioid Endometrial Cancer RECRUITING NCT05705505
ON123300 DRUG Phase PHASE1 Solid Tumors, Adult RECRUITING NCT04739293
Nivolumab DRUG Phase PHASE1 Non-small Cell Lung Cancer COMPLETED NCT04263090
Quality-of-Life Assessment OTHER Phase EARLY_PHASE1 Recessive Dystrophic Epidermolysis Bullosa COMPLETED NCT04177498
Rigosertib Sodium DRUG Phase EARLY_PHASE1 Recessive Dystrophic Epidermolysis Bullosa COMPLETED NCT04177498
Questionnaire BEHAVIORAL Phase PHASE2 Leukemia TERMINATED NCT02730884
Rigosertib DRUG Phase PHASE1 Non-small Cell Lung Cancer COMPLETED NCT04263090
best supportive care (BSC) DRUG Phase PHASE3 Myelodysplastic Syndrome TERMINATED NCT02562443
Any approved or standard-of-care therapy DRUG Phase PHASE3 Myelodysplastic Syndrome TERMINATED NCT02562443
briciclib DRUG Phase PHASE1 Neoplasms TERMINATED NCT02168725
Radiotherapy RADIATION Phase PHASE1 Head and Neck Neoplasms COMPLETED NCT02107235
cisplatin DRUG Phase PHASE1 Head and Neck Neoplasms COMPLETED NCT02107235
Azacitidine DRUG Phase PHASE1 Myelodysplastic Syndrome COMPLETED NCT01926587
oral rigosertib DRUG Phase PHASE1 Head and Neck Neoplasms COMPLETED NCT02107235
Oral rigosertib DRUG Phase PHASE2 Myelodysplastic Syndromes COMPLETED NCT01904682
rigosertib sodium DRUG Phase PHASE3 Myelodysplastic Syndromes COMPLETED NCT01928537
ON 01910.Na Concentrate DRUG Phase PHASE1 Myelodysplastic Syndrome WITHDRAWN NCT00867061
rigosertib DRUG Phase PHASE3 Myelodysplastic Syndrome TERMINATED NCT02562443
Gemcitabine DRUG Phase PHASE3 Metastatic Pancreatic Adenocarcinoma COMPLETED NCT01360853
gemcitabine DRUG Phase PHASE1 Malignant Neoplasmas COMPLETED NCT01125891
ON 013105 DRUG Phase PHASE1 Lymphoma TERMINATED NCT01049113
oxaliplatin and ON 01910.Na DRUG Phase PHASE1 Hepatoma COMPLETED NCT00861783
irinotecan and ON 01910.Na DRUG Phase PHASE1 Hepatoma COMPLETED NCT00861783
ON 01910.Na and oxaliplatin DRUG Phase PHASE1 Advanced Solid Tumors COMPLETED NCT00861328
ON 01910.Na and irinotecan DRUG Phase PHASE1 Advanced Solid Tumors COMPLETED NCT00861328
ON 01910.Na DRUG Phase PHASE3 Metastatic Pancreatic Adenocarcinoma COMPLETED NCT01360853
Total products: 84